The National Gastro-Intestinal Cancer Audit Programme comprises both the National Bowel Cancer Audit and the National Oesophago-Gastric Cancer Audit which were previously managed as two separate audits.
The National Bowel Cancer Audit evaluates the quality of care received by patients with bowel cancer in England and Wales. Its aim is to assess the organisation of cancer services as well as the diagnosis and staging process and the outcomes of treatment.
For this Audit, we are seeking an enthusiastic consultant colorectal surgeon who will provide clinical leadership to the Audit’s Project Team in partnership with the clinical co-lead for oncology (Dr Mike Braun, Medical Oncologist, Christie Hospital, Manchester). The co-leads provide one clinical session per week to advise on clinical aspects of the Audit, liaise with the clinical community, champion the Audit, and attend regular team meetings. The current Co-Lead for Surgery, Professor James Hill, is stepping down after having served in this role since 2015.
The Audit has until now focused primarily on bowel cancer patients who are treated surgically. The clinical co-leads support widening the scope of the Audit (including all bowel cancer patients, not only those treated surgically) and to extend its time horizon (earlier in the patient pathway before diagnosis and later in the pathway assessing longer-term outcomes).
The Audit is funded by the Healthcare Quality Improvement Partnership. It is carried out by the Clinical Effectiveness Unit of the Royal College of Surgeons of England in partnership with the Association of Coloproctology of Great Britain and Ireland, and NHS Digital.
The post is offered until 31 May 2021. NHS Employers will be reimbursed for the one clinical session per week.
Applications should be sent to Professor Jan van der Meulen, Clinical Effectiveness Unit, RCSE, 35-43 Lincoln’s Inn Fields, London WC2A 3PE by 2 November 2018 at 5 pm and include a letter detailing your reasons for applying for this position and a copy of your curriculum vitae.